Valuation: Cara Therapeutics, Inc.

Market Cap 24.33M 21.15M 19.69M 18.08M 34.13M 2.32B 34.66M 232M 91.08M 1.16B 91.38M 89.37M 3.88B P/E 2023
-0.34x
P/E 2024 -0.39x
Enterprise Value 30.88M 26.84M 24.98M 22.94M 43.32M 2.95B 43.99M 294M 116M 1.47B 116M 113M 4.92B EV / Sales 2023
-0.82x
EV / Sales 2024 4.84x
Free-Float
-
Yield 2023 *
-
Yield 2024 -

Financials

2023 2024
Net sales 20.97M 18.23M 16.97M 15.58M 29.42M 2B 29.87M 200M 78.49M 996M 78.75M 77.02M 3.34B 7.14M 6.2M 5.77M 5.3M 10.01M 681M 10.17M 68.07M 26.72M 339M 26.8M 26.21M 1.14B
Net income -119M -103M -95.89M -88.04M -166M -11.31B -169M -1.13B -444M -5.63B -445M -435M -18.89B -70.87M -61.6M -57.34M -52.65M -99.42M -6.76B -101M -676M -265M -3.37B -266M -260M -11.29B
Net Debt -57.59M -50.06M -46.6M -42.78M -80.79M -5.5B -82.04M -549M -216M -2.74B -216M -212M -9.18B 6.54M 5.69M 5.3M 4.86M 9.18M 625M 9.32M 62.42M 24.5M 311M 24.58M 24.04M 1.04B
Logo Cara Therapeutics, Inc.
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Employees
-
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B